Business Context and Reporting Period
This Form 8-K is filed by 60 Degrees Pharmaceuticals, Inc. (SXTP) on January 20, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive office in Washington, D.C. The filing addresses a critical corporate governance event regarding the listing status of its securities on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the $20,000 hearing fee paid by the Company to request an appeal of the delisting determination.
Material Changes
The primary material change reported is the receipt of a written notice from Nasdaq staff determining that the Company's common stock and warrants will be delisted. This determination is based on the failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Notably, the Company is ineligible for the standard 180-day compliance period because it executed a 1-for-5 reverse stock split on February 24, 2025, within the prior one-year period. Consequently, the Company is subject to immediate delisting.
Outlook, Risks, and Management Commentary
- Appeal Process: The Company has paid the required fee and formally requested an appeal with Nasdaq. This action stays the suspension of trading and the filing of Form 25-NSE pending the Panel's decision.
- Uncertainty: Management explicitly states there can be no assurance that the Panel will grant the request for continued listing.
- Warrant Impact: The Company's warrants (SXTPW) are also subject to delisting under Nasdaq Listing Rule 5560(a) because the underlying common stock is being delisted.
Investor Verification Checklist
- Verify the current trading status of SXTP and SXTPW on Nasdaq to confirm if trading has been suspended pending the appeal.
- Monitor the outcome of the Nasdaq Panel's decision regarding the appeal, as immediate delisting is the default outcome if the appeal fails.
- Review the Company's recent stock price history to understand the context of the 1-for-5 reverse stock split executed in February 2025.
- Check for subsequent filings (e.g., Form 25-NSE) which would confirm the final delisting if the appeal is denied.